Clinical trials: Metastatic Esophageal Cancer
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030862
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III
- Trial name
- NCT03993353
- Testing
- Pembrolizumab, Tadalafil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Esophageal Cancer
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00861094
- Testing
- cisplatin, 5-FU, oxaliplatin
- Where
- 28 sites in France
- Volunteers
- 266 people
- Sponsor
- UNICANCER
Esophageal Cancer, Esophageal Squamous Cell Carcinoma
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with…
- Conditions
- Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Trial name
- NCT06010303
- Testing
- LBL-007, Tislelizumab, Chemotherapy Doublet
- Where
- 38 sites in China, South Korea and 2 more
- Volunteers
- 118 people
- Sponsor
- BeiGene
Colorectal Cancer, Depression
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00387348
- Testing
- escitalopram oxalate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has…
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07392892
- Testing
- PF-08634404, Chemotherapy, Nivolumab
- Where
- 102 sites in United States, Canada and 8 more
- Volunteers
- 840 people
- Sponsor
- Pfizer
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Esophageal Squamous Cell Carcinoma
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a common malignant disease worldwide especially in china. Though esophagectomy and definitive chemoradiotherapy are standard treatments, disease relapses in many patients and the prognosis of metastatic ESCC…
- Trial name
- NCT03251417
- Testing
- Irinotecan, Apatinib
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Peking University
Esophagus Squamous Cell Carcinoma (SCC), Metastatic Cancer
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed.
- Trial name
- DOSE (NCT03585673)
- Testing
- Docetaxel-PM, Oxaliplatin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sung Yong Oh
Liver Diseases, Liver Cancer
Liver Transplantation for Unresectable GIST Liver Metastases
Liver Transplantation for Unresectable GIST Liver Metastases
- Conditions
- Liver Diseases, Liver Cancer, Liver Metastases, Liver Neoplasms
- Trial name
- TRANSGIST (NCT04825470)
- Testing
- Liver Transplantation
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario Virgen de la Arrixaca
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Esophageal Cancer
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00107341
- Testing
- bortezomib, carboplatin, paclitaxel
- Volunteers
- 37 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Squamous Cell Carcinoma
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable…
- Trial name
- NCT06022861
- Testing
- LY01015, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Esophageal Cancer, Toxicity
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
Oesophagogastric cancer is a major cause of cancer related mortality, with an overall 5-year survival rate of 10% worldwide and patients are often diagnosed with locally advanced or metastasized disease at first presentation.
- Trial name
- ACTION (NCT02273713)
- Testing
- Nab-paclitaxel
- Where
- Netherlands
- Volunteers
- 154 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Esophageal Cancer
Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
The goal of this observational study is to learn about in health conditions of ESCC. The main question[s] it aims to answer are: •Lymph node metastasis(LNM) in cervical paraesophageal or supraclavicular which influence OS more.
- Trial name
- ECPLNMvsSLNM (NCT06165094)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute